Key points from article :
Two US patients recovered from untreatable infections with engineered bacteriophages (bacteria-killing viruses).
The therapy provided hope for addressing drug-resistant infections where conventional antibiotics had failed.
One patient, a 26-year-old with cystic fibrosis, cleared a chronic lung infection resistant to antibiotics, enabling a lung transplant.
Another, a 56-year-old with severe arthritis, showed remarkable recovery from an untreatable skin infection.
These successful cases are expected to lead to upcoming clinical trials for phage therapy, possibly launching next year.
Phage therapy presents a promising alternative for patients with no other treatment options due to antibiotic resistance.
The therapy comes amid a global crisis of antimicrobial-resistant infections, with millions of deaths attributed to these infections.
Research by Prof Graham Hatfull at the University of Pittsburgh published in Cell and Nature Communications.
